• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

1例使用霉酚酸酯和利妥昔单抗成功治疗但未使用糖皮质激素的抗合成酶综合征病例。

A Case of Anti-Synthetase Syndrome Successfully Treated with Mycophenolate Mofetil and Rituximab but No Corticosteroids.

作者信息

Sieradzka Agnieszka Ewa, Naccini Bruno, Fontana Massimiliano

机构信息

Private Practice, Riva San Vitale, Ticino, Switzerland.

Pneumology Service, Ospedale Beata Vergine, Mendrisio, Ticino, Switzerland.

出版信息

Eur J Case Rep Intern Med. 2022 Jul 18;9(7):003324. doi: 10.12890/2022_003324. eCollection 2022.

DOI:10.12890/2022_003324
PMID:36051166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9426970/
Abstract

UNLABELLED

A patient with antisynthetase syndrome with pulmonary and muscular involvement was treated with immunosuppressive agents without corticosteroids. Rituximab was added to mycophenolate mofetil therapy with improvement in lung functional and imaging findings and normalization of creatine kinase levels.

LEARNING POINTS

Antisynthetase syndrome associated with interstitial lung disease (ILD) and myopathy can be successfully treated without corticosteroids.A combination of several immunosuppressive agents can be a therapeutic alternative in case of refractory ILD.

摘要

未标注

一名患有抗合成酶综合征且伴有肺部和肌肉受累的患者接受了无皮质类固醇的免疫抑制剂治疗。在霉酚酸酯治疗中加用了利妥昔单抗，肺功能和影像学表现得到改善，肌酸激酶水平恢复正常。

学习要点

与间质性肺病（ILD）和肌病相关的抗合成酶综合征无需使用皮质类固醇即可成功治疗。对于难治性ILD，几种免疫抑制剂联合使用可能是一种治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cd/9426970/83de32774369/3324_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cd/9426970/81bce6aae98e/3324_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cd/9426970/edc75f35e9e9/3324_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cd/9426970/d75641bee7c8/3324_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cd/9426970/6b1a3858a867/3324_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cd/9426970/83de32774369/3324_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cd/9426970/81bce6aae98e/3324_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cd/9426970/edc75f35e9e9/3324_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cd/9426970/d75641bee7c8/3324_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cd/9426970/6b1a3858a867/3324_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cd/9426970/83de32774369/3324_Fig5.jpg

相似文献

1
A Case of Anti-Synthetase Syndrome Successfully Treated with Mycophenolate Mofetil and Rituximab but No Corticosteroids.1例使用霉酚酸酯和利妥昔单抗成功治疗但未使用糖皮质激素的抗合成酶综合征病例。
Eur J Case Rep Intern Med. 2022 Jul 18;9(7):003324. doi: 10.12890/2022_003324. eCollection 2022.
2
A 65-year-old Woman With Persistent Dyspnea, Arthritis, and Raynaud's Phenomenon.一位 65 岁女性，持续性呼吸困难、关节炎和雷诺现象。
Am J Med Sci. 2021 Apr;361(4):526-533. doi: 10.1016/j.amjms.2020.11.012. Epub 2020 Nov 22.
3
Jo1-antisynthetase syndrome and severe interstitial lung disease with organising pneumonia on histopathology with favourable outcome on early combined treatment with corticosteroids, mycophenolate mofetil and rituximab.Jo1抗合成酶综合征与严重间质性肺疾病，组织病理学显示机化性肺炎，早期联合使用皮质类固醇、霉酚酸酯和利妥昔单抗治疗效果良好。
BMJ Case Rep. 2019 Sep 12;12(9):e231006. doi: 10.1136/bcr-2019-231006.
4
Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.利妥昔单抗治疗Jo1抗体相关抗合成酶综合征：抗Ro52阳性作为病情严重程度和治疗反应的标志物
J Rheumatol. 2016 Aug;43(8):1566-74. doi: 10.3899/jrheum.150844. Epub 2016 Jun 1.
5
[Clinical and radiological features of adult patients with different antisynthetase syndrome based on serum anti-aminoacyl-tRNA synthetase antibody type].[基于血清抗氨酰tRNA合成酶抗体类型的不同抗合成酶综合征成年患者的临床和放射学特征]
Zhonghua Jie He He Hu Xi Za Zhi. 2017 Dec 12;40(12):919-924. doi: 10.3760/cma.j.issn.1001-0939.2017.12.011.
6
Management of Myositis-Associated Interstitial Lung Disease.肌炎相关间质性肺疾病的管理
Medicina (Kaunas). 2021 Apr 3;57(4):347. doi: 10.3390/medicina57040347.
7
Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review.与间质性肺病相关的低肌病性皮肌炎及对霉酚酸酯反应良好：病例回顾
Clin Rheumatol. 2017 Aug;36(8):1919-1926. doi: 10.1007/s10067-017-3671-0. Epub 2017 May 9.
8
Antisynthetase syndrome.抗合成酶综合征。
Curr Rheumatol Rep. 2011 Jun;13(3):175-81. doi: 10.1007/s11926-011-0176-8.
9
Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy.霉酚酸酯治疗伴有或不伴有钙调磷酸酶抑制剂治疗抵抗性炎性肌病。
Clin Rheumatol. 2019 Feb;38(2):585-590. doi: 10.1007/s10067-018-4294-9. Epub 2018 Sep 14.
10
Subcutaneous immunoglobulins for the treatment of a patient with antisynthetase syndrome and secondary chronic immunodeficiency after anti-CD20 treatment: a case report.皮下注射免疫球蛋白治疗抗合成酶综合征及抗CD20治疗后继发慢性免疫缺陷患者：一例报告
J Med Case Rep. 2017 Mar 4;11(1):58. doi: 10.1186/s13256-017-1211-9.

引用本文的文献

1
Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome.利妥昔单抗治疗抗合成酶综合征相关进行性间质性肺病。
Arthritis Res Ther. 2024 Jun 18;26(1):122. doi: 10.1186/s13075-024-03353-2.
2
A Case of Overlapping Autoimmune Syndrome.重叠自身免疫综合征一例。
Cureus. 2024 May 6;16(5):e59714. doi: 10.7759/cureus.59714. eCollection 2024 May.

本文引用的文献

1
Clinical manifestations and treatment of antisynthetase syndrome.抗合成酶综合征的临床表现和治疗。
Best Pract Res Clin Rheumatol. 2020 Aug;34(4):101503. doi: 10.1016/j.berh.2020.101503. Epub 2020 Apr 11.
2
Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis.特发性炎性肌病相关间质性肺病的治疗：系统评价和荟萃分析。
Autoimmun Rev. 2019 Feb;18(2):113-122. doi: 10.1016/j.autrev.2018.07.013. Epub 2018 Dec 17.
3
Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review.
利妥昔单抗治疗抗合成酶综合征相关的间质性肺病：一项多中心回顾性病例研究。
J Rheumatol. 2018 Jun;45(6):841-850. doi: 10.3899/jrheum.170541. Epub 2018 Apr 1.
4
The Diagnosis and Treatment of Antisynthetase Syndrome.抗合成酶综合征的诊断与治疗
Clin Pulm Med. 2016 Sep;23(5):218-226. doi: 10.1097/CPM.0000000000000171.
5
Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.利妥昔单抗治疗Jo1抗体相关抗合成酶综合征：抗Ro52阳性作为病情严重程度和治疗反应的标志物
J Rheumatol. 2016 Aug;43(8):1566-74. doi: 10.3899/jrheum.150844. Epub 2016 Jun 1.
6
Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.抗合成酶综合征相关间质性肺病中利妥昔单抗的长期经验。
Rheumatology (Oxford). 2015 Aug;54(8):1420-8. doi: 10.1093/rheumatology/kev004. Epub 2015 Mar 3.
7
Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease.钙调磷酸酶抑制剂在抗合成酶相关间质性肺疾病患者队列中的应用。
Clin Exp Rheumatol. 2013 May-Jun;31(3):436-9. Epub 2013 Mar 7.
8
Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.利妥昔单抗治疗抗合成酶综合征相关难治性间质性肺病。
Respir Med. 2012 Apr;106(4):581-7. doi: 10.1016/j.rmed.2012.01.001. Epub 2012 Jan 24.
9
Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.特发性炎性肌病的药物治疗：对泼尼松、硫唑嘌呤和甲氨蝶呤反应的预测因素及其疗效比较
Am J Med. 1993 Apr;94(4):379-87. doi: 10.1016/0002-9343(93)90148-i.